Although the contribution of the bone marrow mesenchymal stem cells (BM-MSCs) in cancer progression is emerging, their potential roles in prostate cancer (PCa) remain unclear. Here, we showed that PCa cells could recruit BM-MSCs and consequently the metastatic ability of PCa cells was increased. We also found that the increased metastatic ability of PCa cells could be due to the increased PCa stem cell population. Mechanism dissection studies found that the upregulation of Chemokine ligand 5 (CCL5) expression in BM-MSCs and PCa cells, after MSCs infiltrated into the PCa cells, subsequently downregulated androgen receptor (AR) signaling, which was due to inhibition of AR nuclear translocation. Interruption of such signaling led to suppression of the BM-MSCs-induced PCa stem cell population increase and thereby inhibited the metastatic ability of PCa cells. The PCa stem cell increase then led to the upregulation of matrix metalloproteinase 9, ZEB-1, CD133 and CXCR4 molecules, and enhanced the metastatic ability of PCa cells. Therefore, we conclude that the BM-MSCs-mediated increased metastatic ability of PCa cells can be due to the PCa stem cell increase via alteration of the CCL5-AR signaling pathway. Together, these results uncover the important roles of BM-MSCs as key components in the prostate tumor microenvironment to promote PCa metastasis and may provide a new potential target to suppress PCa metastasis by blocking BM-MSCs infiltration into PCa.
INTRODUCTION
Several kinds of cells in the tumor microenvironment (TME), including macrophages, endothelial cells and fibroblasts, contribute to prostate cancer (PCa) progression. [1] [2] [3] Several studies showed that the bone marrow-derived mesenchymal stem cell (BM-MSCs) also contributed to various tumor progressions. [4] [5] [6] [7] However, BM-MSCs have been shown to have both beneficial and harmful effects. Transplantation of BM-MSCs into injured tissues exhibited promising effects, [8] [9] [10] and they also serve as therapeutic tools to effectively carry target molecules into cancer cells. [11] [12] [13] In contrast, several reports have suggested BMMSCs affect cancer progression, angiogenesis and metastasis. [4] [5] [6] [7] Importantly, no solid data have been reported to conclude whether the BM-MSCs can affect PCa progression.
We investigated the contribution of BM-MSCs in PCa metastasis using in vitro and in vivo approaches, and revealed that BM-MSCs could be recruited to tumor sites and then promote PCa stem cells population and metastatic ability. We also dissected potential mechanisms that might be involved in the modulation of androgen receptor (AR) signaling.
RESULTS

PCa cells have the capacity to recruit the circulating BM-MSCs
Recent reports demonstrated that circulating BM-MSCs could migrate to various tumor sites. 14, 15 To investigate whether circulating BM-MSCs could be recruited into the prostate tumor site, we isolated primary BM-MSCs from mice. Flow cytometric analysis results showed expression of the BM-MSCs markers (Supplementary Table 1 ) and their ability to differentiate into multilineage cells (Supplementary Figure 1A) . We performed Boyden chamber migration assays using these cells (Figure 1a) . After 24 h incubation, the PCa cells (LNCaP, C4-2 and CWR22Rv1), but not the normal prostate epithelial (RWPE-1) cells, significantly induced BM-MSCs migration (Figure 1b) . We also found BM-MSCs have higher expressions of matrix metalloproteinase 9 (MMP9), which is a key molecule in modulation of cell motility, 16 upon coculture with PCa cells, but not with normal prostate RWPE-1 cells (Figure 1c ). These studies were further confirmed in CWR22Rv1 orthotopic xenograft mouse model. The green fluorescent protein (GFP)-labeled BM-MSCs that had been isolated from GFP mice were injected into the CWR22Rv1 xenografted mice tail veins after tumors develop. As shown in Figure 1d , GFP signals were detected in prostate tumors, but not in normal prostate tissues when analyzed by the in vivo imaging system (IVIS). Immunohistochemical staining also showed high numbers of GFP-positively stained cells in prostate tumors tissues (Figure 1e ), but not in normal prostate tissues. These results imply that BM-MSCs can migrate into prostate tumor sites, but not into the normal prostate.
Consistently, we detected higher numbers of the 5-bromo-2'-deoxyuridine-stained BM-MSCs cells upon PCa cells CM treatment (Figure 1g ), suggesting that PCa cells could promote BM-MSCs proliferation when recruited to tumor sites. This is important as there are limited numbers of circulating BM-MSCs; accelerated proliferation by PCa cells might be favorable for exerting their action.
The recruited BM-MSCs influence PCa cell invasion We next studied the influence of the infiltrated BM-MSCs on in vitro invasion ability of PCa cells and in vivo metastasis. We found the in vitro invasion abilities of PCa cells were significantly increased upon mouse primary BM-MSCs (Figures 2b and c) and human BM-MSCs (Figure 2d ) coculture.
To confirm the above in vitro cell lines results in in vivo mice studies, we developed a CWR22Rv1 orthotopic xenograft mouse model. For monitoring metastasis, luciferase-incorporated CWR22Rv1 (luc-CWR22Rv1) cells were developed and implanted, either alone or as the mixture of luc-CWR22Rv1 cells and primary BM-MSCs (CWR22Rv1: BM-MSCs, 10:1) for xenografts. After 3 weeks, we started to use the IVIS system to monitor the luminescence signal of the tumors once a week (3, 4, 5 and 6 weeks). At week 5, we found that the two groups of mice developed similar-sized tumors, but the CWR22Rv1-/BM-MSCs-co-implanted mice showed higher luminescence signals at proximal lymph nodes and distant organs compared with control mice (Figure 2e and Supplementary  Figure 2A) . We confirmed higher metastasis in the co-implantation group after killing (Figures 2f-g ). The luciferase staining results of tissues obtained from diaphragms of the co-implanted group confirmed the origin of the metastasized tumors (Figure 2h ). We also found higher MMP9-positively stained cells in prostate tumor tissues of the co-implanted group compared with control mice (Figure 2i ). Detection of tumor cells in the ascitic fluids have been reported to be an important indication of tumor metastasis. 17 We found ascitic fluids (6 out of 10 mice, 60%) in most of the co-implanted group, whereas only a few control mice had ascites (3 out of 20 mice, 15%). The luminescence signal in the ascites cells indicated they originated from the injected CWR22Rv1 cells (Supplementary Figure 2B) . BM-MSCs coculture/co-implantation increased PCa stem cell population Interestingly, when we cocultured PCa cells with BM-MSCs, we found some PCa cells grew as floating spheres, which is known to be the characteristic of stem cells. 18 Therefore, we investigated the influence of BM-MSCs on the PCa stem cell population increase by flow cytometry and found that the BM-MSCs coculture led to increased CD133 þ cell population [19] [20] [21] (Figure 3a) . The immunofluorescence staining results also demonstrated increased CD133 þ cells in LNCaP and C4-2 cells upon BM-MSCs coculture (Figure 3b ). We also found increased expressions of stem cell markers, such as CD133, OCT4 and SOX2 22, 23 in PCa cells upon BM-MSCs coculture (Figure 3c) . We confirmed the above in vitro cell line studies results in in vivo mice studies by showing tumor tissues of the CWR22Rv1-/BM-MSCs-co-implanted group of mice had higher numbers of CD133 þ and CD44 þ cells compared with control mice (Figure 3d ). We also performed the sphere formation assay, which is the well-defined method to examine stem cell self-renewal capacity. [24] [25] [26] The sphere's size and numbers were increased when PCa cells were cocultured with mouse primary BM-MSCs compared with control (PCa cells alone; Figure 3e ), and with human primary cultured BM-MSCs (Figure 3f ). To test whether PCa stem cells increase was due to the increase in their self-renewal ability, we isolated the CD133 þ population of LNCaP and C4-2 cells by magnetic sorting method using CD133 antibody, and sphereforming abilities were tested, with or without BM-MSCs coculture. We found that BM-MSCs coculture increased the self-renewal ability of CD133 þ stem cells (Figure 3g ). This data indicated the BM-MSCs effect in increasing stem cell population might be due to increasing the self-renewal ability of the original stem cell population within Higher population of stem cells in PCa led to more metastatic potential We found higher invasion ability of CD133 þ cells from the LNCaP cell line (Figure 3h ) and the C4-2 cell line ( Figure 3h ) than the CD133 À cells, consistent with the previous reports. 6, 27, 28 Expressions of the metastasis-associated genes, including ZEB-1, Snail, CXCR4 and MMP9, [29] [30] [31] were also shown higher in the C4-2 CD133 þ cells than in CD133 À cells (Figure 3i ). When we cocultured C4-2 cells with BM-MSCs, we found increased expressions of these genes (Figure 3j ). These results suggest that the BM-MSCs-mediated increased PCa stem cell population may be responsible for the enhanced metastatic ability of PCa cells. Downregulation of AR signaling in PCa cells is essential for BMMSCs action AR is the most important molecule in mediating PCa progression, and even in castration-resistant PCa the AR expression persists, 32 and its linkage and impact on PCa progression continues. 33 However, recent studies suggested that AR might have differential roles depending on the individual cell type within the PCa TME and tumor stage. 34, 35 When we investigated BM-MSCs effect on AR signaling in LNCaP and C4-2 cells, we found little change in AR expression levels (Figure 4a ), but significant suppression of luciferase activity ( Figure 4b ) and AR downstream genes expressions, including prostate-specific antigen (PSA), TMPRSS2 and FKBP5 (Figure 4c) . The decreased PSA level was also detected in tumor tissues obtained from CWR22Rv1-/BM-MSCs-co-implanted xenografted mice (Supplementary Figure 3A ). We further found significantly decreased AR nuclear translocation in PCa cells upon BM-MSCs coculture (Figure 4d ), which might be the mechanism by which BM-MSCs downregulate the AR signaling in PCa cells.
On the basis of the recent paper by Lee et al., 36 AR had a suppressor role in self-renewal of PCa stem/progenitor cells. We were interested to know whether the AR downregulation is essential in exerting BM-MSCs' action promoting PCa stem cell population increase. We used the PC3 cell line (PCa cells lacking AR) and PC3AR9 cell line (PC3 cells stably transfected with functional human natural AR), 37 and cocultured both with BMMSCs to test whether we could observe PCa stem cell increase under both AR conditions. We found significant changes in sphere-forming ability ( Figure 4e ) and CD133 expression (Figure 4f, left panel) of the PC3AR9 cells upon BM-MSCs coculture, but failed to detect stem cells increase in the AR-negative PC3 cells. Similar results were obtained when we tested C4-2-AR-small interfering RNA (siRNA, AR knockdown by lentiviral infection is shown in Supplementary Figure 3B ) and C4-2-scrambled control cells. However, we found no significant changes in sphere-forming ability (Figure 4g ) and CD133 expressions (Figure 4f , right panel) in the AR knocked-down C4-2-AR-siRNA cells upon BM-MSCs coculture.
We confirmed the above in vitro results with in vivo mice studies. The PC3 cell-derived orthotopic xenograft mouse model was developed. Mice groups were implanted with either PC3 cells alone or the mixture of PC3 cells and BM-MSCs. As shown in Figure 4h , we found little changes in CD133 þ cell numbers in prostate tumor tissues obtained from the two mice groups, suggesting that BMMSCs failed to increase the stem cell population when AR is absent.
We then tested whether we could observe the BM-MSCs effect in increasing metastasis in AR-negative PC3 cells. As expected, the invasion ability (Figure 4i ) and MMP9 expression (Figure 4j and affect tumorigenicity and angiogenesis of cancer. 40 Using the arrays to compare the cytokine levels in the CM obtained from coculture of C4-2 cells/BM-MSCs vs C4-2 cell culture, we found the secretions of IP-10 and CCL5 were most dramatically increased in BM-MSCs upon PCa coculture (Figure 5a ), while decreases in some cytokines including interleukin-6 and interleukin-8 were observed. CCL5 increase was observed to mediate the BM-MSCs action in promoting breast cancer metastasis, 5 so we determined to select this molecule for further studies. We validated significantly increased CCL5 mRNA expression in BM-MSCs upon coculture with various PCa cells (Figure 5b ). We also detected dramatic increase of CCL5 in PCa cells (Figure 5c ), suggesting that BM-MSCs BM-MSCs increase stem cells PCa population and metastatic ability J Luo et al and PCa cells interact to influence CCL5 secretion in both cell types. We found significantly increased CCL5 staining in tumor tissues obtained from CWR22Rv1-/BM-MSCs-co-implanted xenografted mice compared with tissues of CWR22Rv1 cells-injected mice (Figure 5d ).
In addition, adding recombinant CCL5 led to increased CD133 and MMP9 mRNA expressions (Figure 5e ), and recombinant CCL5 effects on increases in stem cell population and invasion ability were also demonstrated in sphere formation (Figure 5f ) and invasion (Figure 5g ) assays. We then found suppression of AR luciferase activity (Figure 5h ) and PSA level decrease (Figure 5i ) when recombinant CCL5 was added into various PCa cells. Furthermore, we showed that recombinant CCL5 suppressed AR nuclear accumulation (Figure 5j ) and induced expressions of the metastasis-associated genes, ZEB-1, Snail and CXCR4, (Figure 5k) . We also performed neutralizing experiments adding the CCL5-neutralizing antibody into PCa cells and found significantly suppressed BM-MSCs effect in increasing stem cell population (Figure 5l ) and invasion ability (Figure 5m) . Effects of the CCL5 antibody on blocking the metastasis-associated gene expressions were also demonstrated (Figure 5n and Supplementary Figure 3C ). These results demonstrate that CCL5 is a strong candidate molecule to downregulate AR signaling, which is essential in increasing stem cell population and metastatic ability of PCa cells.
We tested in which cell type (PCA or MSCs) the CCL5 has the central role in promoting metastasis. When we cocultured the CCL5 knocked-down C4-2 (C4-2-siCCL5) cells with BM-MSCs, there was no longer increased invasion of C4-2-siCCL5 cells. We then cocultured C4-2 cells with the CCL5 knocked-down BM-MSCs cells and observed no increase in C4-2 cells invasion, either. The further mechanism dissection also showed that expressions of the target genes did not change significantly after coculture of these two types of cells no matter in which cell type CCL5 expression was knocked down. So, we can conclude that CCL5 increase is essential in both types of cells (PCa and MSCs; Supplementary Figure 3D and Figure 5o ).
DISCUSSION
The BM-MSCs contribution in tumor growth and metastasis of other cancers and their roles in differentiation into stromal cells has been studied, [4] [5] [6] [7] 41 but relatively little has been understood about their role in PCa progression, especially its linkage to AR signaling. We found that BM-MSCs could be recruited into the prostate tumor site and lead to increase metastatic ability, possibly via increasing PCa stem cell population. Previous studies also suggested that the increase in stem cell population might lead to enhanced PCa metastasis, 6, 27, 28, 42 which matched well with our results showing higher invasion ability (Figure 3h ) and higher expressions of the metastasis-associated genes, including ZEB-1, Snail, CXCR4 and MMP9 (Figure 3i ) in the isolated CD133 þ stem cells than in the CD133 À cells.
We performed in vitro studies using both BM-MSCs CM and the coculture system. Under these conditions, BM-MSCs influences are expected to be through the paracrine action. We also used a culture system by placing PCa cells into the plates that already had BM-MSCs growing, so the two types of cells could contact and interact with each other. Under this condition, PCa cells were growing on the top of BM-MSCs, but PCa cells were easily removed by pipetting as their contact was not tight, and then the BM-MSCs were collected for further analyses. We observed similar effects with both of these coculture systems. Therefore, we concluded that the BM-MSCs effect was through the paracrine effect mediated by cytokines they secrete no matter what condition we use. We also tested whether BM-MSCs can be differentiated into cancer-associated fibroblasts and we found no cancer-associated fibroblasts-specific marker expression increases in BM-MSCs upon PCa CM treatment. Accordingly, we focused on the paracrine effects of BM-MSCs in these studies.
We used 1:10 ratio of BM-MSCs/PCa cells in both in vitro coculture and in vivo mice studies. BM-MSCs circulate and are recruited into the tumor site and directly interact with PCa cells, so injecting as a mixture of PCa cells and BM-MSCs is considered clinically relavant. The number of BM-MSCs used in these studies may be higher than the real clinical case and somewhat exaggerated, but we used this ratio based on a previous report on breast cancer. 5 It can be speculated that our in vitro and in vivo study conditions might be artificial as properties of BM-MSCs might be altered after they arrive at the PCa TME. We showed BM-MSCs migration into the prostate tumor site (not to the normal prostate), so we believe that the cross talk between BM-MSCs and cancer cells does occur. We also found that our in vivo results were consistent with the in vitro coculture experimental data. For example, we observed CCL5 increase and stem cell increase in the BM-MSCs-co-implanted group mice, suggesting that the in vitro BM-MSCs effect was mimicked in the mice studies.
We elucidated mechanisms by which BM-MSCs increase metastasis and found that BM-MSCs trigger upregulation of CCL5, downregulation of AR, PCa stem cell increase and upregulation of CXCR4/ZEB-1 in PCa cells. We showed that the BM-MSCs function is through their paracrine action by secreting cytokines, and the most critical cytokine molecule for this action was CCL5. Increased secretion of CCL5 and its contribution to breast cancer metastasis has been suggested. 5 We investigated whether AR downregulation is the earlier event and whether this environment favoring stem cells expansion or stem cell increase occurs as a consequence of this downregulation of AR level in PCa cells. We found that BM-MSCs increased PCa stem cell population in the AR-positive PCa cell lines, but not in the AR-negative cell lines, such as PC3, indicating that AR downregulation may be the earlier event and is essential to trigger stem cell increase. Considering the suppressor role of AR in self-renewal of PCa stem cells, 36 it seems that these two processes may cooperate. This newly found CCL5 -AR-CXCR4/ZEB-1 signaling axis could be used to develop future therapeutic approaches to battle PCa ( Figure 6 ). Here we demonstrated that the AR signal downregulation is essential in exerting BM-MSCs action to mediate increased metastatic ability of PCa cells. The downregulation of AR-promoted metastasis may be a new challenging concept as all recent therapeutic approaches target AR signaling and may explain why the current therapy fails and results in more malignant metastatic PCa.
In a previous study, we demonstrated the suppressor role of AR in PCa metastasis, 34 and our studies on the TRAMP derivative of the prostate epithelial-specific ARKO mice also demonstrated the differential AR roles in PCa initiation (promoter) vs metastasis (suppressor). 35 It was also reported that the AR downregulation could promote epithelial-mesenchymal transition, suggesting that AR might function as a suppressor during the metastasis process. 43 Moreover, PCa stem cells have higher metastatic ability and these cells also lack AR expression. 36 We could not observe BM-MSCs effect in increasing the invasion ability when AR signal was absent or low (in PC3 and C4-2ARsi cells) and our in vivo results showed no significant difference in metastasis in the PC3 cellsimplanted mice and the PC3-/BM-MSCs-co-implanted mice. These results contrast with the recently published result showing increased invasion ability of the PC3 cells upon incubation with human MSCs in vitro. 41 So, we believe that the future therapeutic strategies should be focused on simultaneous targeting of ARmediated PCa growth and AR downregulation-mediated metastasis.
As targeting the promoter role and suppressor role of AR at the same time is impossible, revealing the signal paradigm, and especially unveiling the downstream molecules of the suppressor role of AR, such as CXCR4/ZEB-1, will be of great significance for exploiting these signals for development of therapeutic approaches to block metastasis.
In conclusion, we showed the importance of BM-MSCs as one component in the PCa TME and as an important contributor in increasing PCa metastasis. It should be noted that BM-MSCs may not be the only contributor to the increased metastatic ability of PCa cells, but our studies clearly demonstrated their importance. This information will add to our current understanding of the TME in influencing PCa progression.
MATERIALS AND METHODS
Cell culture
LNCaP, C4-2, C81 and CWR22Rv1 cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in Roswell Park Memorial Institute media 1640 with 10% fetal bovine serum. Mouse primary BM-MSCs were isolated from wild-type C57BL/6 mice and C57BL/6-Tg (UBC-GFP) mice (The Jackson Laboratory, Bar Harbor, ME, USA) and cultured in Dulbecco's modified Eagle media with 15% fetal bovine serum, 1 Â nonessential amino acids and 10 mM hydroxyethyl piperazine ethane sulfonic acid. Human BM-MSCs were purchased from StemCell Technologies Inc. (Vancouver, BC, Canada) and cultured in Human MesenCult Proliferation Kit (StemCell Technologies Inc.). All cells were maintained in a humidified 5% CO 2 environment at 37 1C.
Cell invasion assay
Six-(0.4 mm pore size) or 24-well (8 mm pore size) transwell plates (Corning, Lowell, MA, USA) were used for coculture and invasion assay, respectively. PCa cells were cocultured with BM-MSCs in transwell plates for 36-48 h. For in vitro invasion assays, transwell plate membranes were pre-coated with diluted Matrigel (20%; BD Biosciences, Sparks, MD, USA) and PCa cells (10 5 cells in serum-free medium) were plated in the upper chamber while 10% serum-containing media placed in the lower chamber. After 36-48 h incubation, cells invaded into the lower chamber were stained with toluidine blue, and positively stained cells were counted. The cell numbers were counted in six random fields. Quantitation indicates means of triplicate repeats ± s.e.m.
Cytokine array CM was collected from PCa cells, BM-MSCs and BM-MSCs-PCa cell coculture and used for cytokine array analyses. The levels of selected panel of cytokines were determined using the Human Antibody Array kit (Affymetrix, Santa Clara, CA, USA; MA6120), following the manufacturer's instructions.
RNA extraction and quantitative real-time PCR analysis
Total RNAs were isolated using Trizol reagent (Invitrogen, Grand Island, NY, USA). One microgram of total RNA was subjected to reverse transcription using Superscript III transcriptase (Invitrogen). Quantitative real-time PCR was conducted using a Bio-Rad CFX96 system (Hercules, CA, USA) with SYBR Green to determine the mRNA expression level of a gene of interest. Expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase level.
Western blot analysis
Cells were lysed in radioimmunoprecipitation assay buffer and proteins (20-40 mg) were separated on 8-10% SDS-polyacrylamide gel electrophoresis, and then transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). After blocking membranes, they were incubated with primary antibodies, horseradish peroxidase-conjugated secondary antibodies and visualized using ECL system (Thermo Fisher Scientific, Rochester, NY, USA). AR, glyceraldehyde 3-phosphate dehydrogenase, tubulin, poly (ADP-ribose) polymerase and GFP antibodies were from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA). MMP9 and CD133 antibodies were from Abcam (Cambridge, MA, USA).
Histology and immunohistochemistry
Tissues obtained were fixed in 10% (v/v) formaldehyde in phosphatebuffered saline, embedded in paraffin and cut into 5-mm sections. Prostate tissue sections were deparaffinized in xylene solution and rehydrated and immunostaining was performed. CCL5 antibody was from R&D (Minneapolis, MN, USA). MMP9, luciferase and CD133 antibodies were from Abcam.
Luciferase assay
PCa cells were plated in 24-well plates and transfected with MMTV-luc containing ARE sequence using Lipofectamine (Invitrogen). After transfection, regular media were added with various dihydrotestosterone concentrations, 0 (ethanol as vehicle control), 1 and 10 nM, and incubated for 48 h. pRL-TK was used as the internal control. Luciferase activity was measured by Dual-Luciferase Assay (Promega, Madison, WI, USA) according to the manufacturer's manual. In vivo BM-MSCs recruitment assay
Male nude mice (6-8 weeks) were used in the studies. One group (six mice) remained untreated, another group (six mice) were injected into the anterior prostates with 1 Â 10 6 CWR22Rv1 cells. After 3 weeks, when tumors grew to palpable size, the primary GFP-labeled BM-MSCs (1 Â 10 5 ) that had been isolated from GFP mice were tail vein injected. Three days later, mice were killed, and GFP signals in normal and tumor prostate tissues were detected by IVIS (Caliper Life Sciences, Hopkinton, MA, USA) and immunohistochemical staining performed. All animal studies were performed under the supervision and guidelines of the University of Rochester Medical Center Animal Care and Use Committee.
In vivo metastasis studies
The nude mice were from the Jackson Laboratory. CWR22Rv1 cells were engineered to express luciferase reporter gene (PCDNA3.0-luciferase) by stable transfection and the positive stable clones (luc-CWR22Rv1) were selected and expanded in culture. Twenty control group mice (6-8 weeks) were injected with luc-CWR22Rv1 cells (1 Â 10 6 , mixed with Matrigel, 1:1) and 10 test group mice were co-injected with PCa cells combined with mouse primary BM-MSCs (1 Â 10 5 ). After 3 weeks, the mice were injected with 150 mg/kg D-Luciferin, and metastasis in live mice was monitored using IVIS at four different time points (3, 4, 5 and 6 weeks after injection). After killing mice at 6 weeks, metastases were analyzed by staining and IVIS. The peritoneal ascites were collected at the killing of mice and luminescence was examined by IVIS.
Statistics
The data values were presented as the mean ± s.d. Differences in mean values between two groups were analyzed by two-tailed Student's t-test. Pp0.05 was considered statistically significant.
